Navigation Links
Verenium Reports Financial Results for the First Quarter Ended March 31, 2011
Date:5/12/2011

SAN DIEGO, May 12, 2011 /PRNewswire/ -- Verenium Corporation (Nasdaq: VRNM), a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, today reported a summary of recent Company highlights and financial results for the first quarter ended March 31, 2011.

"I am pleased with the operational and financial progress made in the first quarter," said James E. Levine, President and Chief Executive Officer at Verenium. "Product revenues from our Grain and Oilseed Processing product lines continue to grow and our next-generation pipeline products have generated strong interest from potential partners. The trends towards higher commodity prices and increased demand for food and transportation fuels will continue to drive growth for products like ours, which provide the operating efficiencies customers value."

Company HighlightsSince the beginning of 2011, Verenium has made significant progress on both operational and financial fronts.  Recent accomplishments include:

Operational/Industry Performance:

Animal Health and Nutrition

  • Grew first quarter 2011 revenues from the Company's animal health and nutrition enzymes over the same period in 2010.

  • Grain Processing

  • Grew first quarter 2011 revenues from the Company's grain processing enzymes, including Fuelzyme® alpha-amylase, Deltazym® GA L-E5 glucoamylase, Veretase® alpha-amylase and Xylathin xylanase, by 26% over the same period in 2010; and
  • Grain processing has grown to represent 30% of 2011 product revenues.

  • Oilseed Processing

  • Achieved significant Purifine® phospholipase C (PLC) revenue growth over 2010 resulting from deployments by Molinos Rio de la Plata and Terminal 6, the
    '/>"/>

  • SOURCE Verenium Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. Verenium Announces 2010 Business Update and Outlook for 2011
    2. Verenium Announces Changes in Senior Management
    3. Verenium Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2010
    4. Verenium Corporation to Announce First Quarter 2011 Financial Results
    5. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
    6. Spherix Reports Second Quarter Earnings
    7. Tapestry Reports Second Quarter 2007 Results
    8. Callisto Reports on Second-Quarter 2007 Milestones
    9. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
    10. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
    11. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:4/21/2015)... ST. LOUIS , April 21, 2015 ... as a 5.4 percent decrease in utilization helped offset ... according to new data released today by Express Scripts ... Express Scripts Workers, Compensation Drug Trend Report discusses the ... opioid use among injured workers. Opioid ...
    (Date:4/21/2015)... , April 21, 2015  The American ... U.S. Food and Drug Administration that the agency,s ... for the last 25 years to protect the ... homeopathic medicines. AAHP, the industry,s trade association, was ... of homeopathic medicines to engage in productive discussions ...
    (Date:4/21/2015)... NEW YORK , April 21, 2015 ... of amendments to its Clinical Trial Authorizations (CTAs) filed ... Regulatory Agency (MHRA) and Germany,s ... (BfArM) for the expansion of the Company,s global Phase ... hepatocellular carcinoma (primary liver cancer, or HCC), to include ...
    Breaking Medicine Technology:Workers' Compensation Prescription Drug Spend Increased 1.9 Percent in 2014, Stabilized by Effective Utilization Management Programs 2Workers' Compensation Prescription Drug Spend Increased 1.9 Percent in 2014, Stabilized by Effective Utilization Management Programs 3Workers' Compensation Prescription Drug Spend Increased 1.9 Percent in 2014, Stabilized by Effective Utilization Management Programs 4Speakers at FDA Hearing Praise Success of Homeopathic Regulatory Framework 2Delcath Receives Approval To Expand Global Phase 2 HCC Program To Include Patients With Intrahepatic Cholangiocarcinoma 2Delcath Receives Approval To Expand Global Phase 2 HCC Program To Include Patients With Intrahepatic Cholangiocarcinoma 3Delcath Receives Approval To Expand Global Phase 2 HCC Program To Include Patients With Intrahepatic Cholangiocarcinoma 4
    ... - First prospective biomarker trial in non-small cell ... /PRNewswire-FirstCall/ -- Response,Genetics, Inc. today announced that positive ... issue of the Journal of Clinical,Oncology suggests that ... in patient biopsies,with advanced non-small cell lung cancer ...
    ... LOS ANGELES--(BUSINESS WIRE)--July 8, 2007 - Cougar Biotechnology,Inc. ... Phase,II data on the Company's prostate cancer drug ... Society for,Medical Oncology (ESMO) Conference, which is currently ... in two oral and,poster presentations on Sunday, July ...
    Cached Medicine Technology:Response Genetics Announces Publication of a Phase III Clinical,Trial Demonstrating That Low Levels of ERCC-1 Help to Predict,Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer 2Response Genetics Announces Publication of a Phase III Clinical,Trial Demonstrating That Low Levels of ERCC-1 Help to Predict,Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer 3Response Genetics Announces Publication of a Phase III Clinical,Trial Demonstrating That Low Levels of ERCC-1 Help to Predict,Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer 4Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ESMO Conference 2Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ESMO Conference 3Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ESMO Conference 4Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ESMO Conference 5Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ESMO Conference 6
    (Date:4/21/2015)... 2015 As a provider of holistic, ... that their rehabilitation strategy, which involves various treatment modalities, ... In an effort to offer hope and encouragement to ... lives, Best Drug Rehabilitation has featured a series of ... successful graduates of their recovery program. , One ...
    (Date:4/21/2015)... Zane Benefits, the leader in individual ... publication of a new guide “Health Reimbursement Accounts in ... the health insurance industry, including how employers can use ... what is permitted when implementing an HRA. This simple, ... which HRAs are compliant this year. , According ...
    (Date:4/21/2015)... April 21, 2015 Zane Benefits, a ... today its CEO Rick Lindquist has been selected as ... , According to Rick Lindquist, “There is a massive ... Zane Benefits’ small business solutions are at its forefront. ... by Employee Benefit Adviser’s Rising Stars.” , According to ...
    (Date:4/21/2015)... 21, 2015 Optimity Advisors ( ... advisory firm that helps clients in complex industries ... that the Association of Community Affiliated Plans ... ACAP represents 58 local, not-for-profit, community-affiliated Safety Net ... million people primarily enrolled in public or state-sponsored ...
    (Date:4/21/2015)... When a bandage sticks to an injury site ... solve this problem two inventors from Festus, Mo., designed ... helps a cut, burn, abrasion or wound heal more ... The bandage is easy to use, versatile and producible ... to the St. Louis office of InventHelp. It is ...
    Breaking Medicine News(10 mins):Health News:Best Drug Rehabilitation Graduate Discusses Making Amends and Rebuilding Relationships 2Health News:Zane Benefits’ CEO Named Top 20 Rising Stars 2Health News:Optimity Advisors Named Preferred Vendor by the Association of Community Affiliated Plans (ACAP) 2
    ... develop certain hereditary cancers develop them at earlier ages than ... CANCER , a peer-reviewed journal of the American Cancer Society, ... of cancer diagnosis to determine when to provide counseling, screening, ... the BRCA genes have a high risk of developing breast ...
    ... , SATURDAY, Sept. 10 (HealthDay News) -- It,s important for ... their children to do their homework, a new study suggests. ... toward homework improves if parents take a positive, supportive attitude ... the assignment or getting a higher grade. The study ...
    ... By Steven Reinberg HealthDay Reporter , FRIDAY, ... Administration advisers recommended Friday that osteoporosis drugs such as ... clarifying how long a patient should take a drug ... drugs, known as bisphosphonates, are taken to prevent fractures ...
    ... Preliminary research on Fusarium , a group of ... shows how these microbes travel through the air. ... research, there will be a better understanding about crop ... are steering their efforts towards a new aerobiological modeling ...
    ... A new study finds that lung cancer patients ... percentage of uninsured and Medicaid-insured patients, so-called "high ... undergo surgery that was intended to cure the ... burden facilities. This difference persisted even after controlling ...
    ... , FRIDAY, Sept. 9 (HealthDay News) -- One-third ... inherited metabolic disorder, a new study finds. This ... produced naturally from many foods -- that has a foul, ... a disease that impairs the ability of an enzyme to ...
    Cached Medicine News:Health News:Women who inherit BRCA gene mutations develop cancer earlier than their ancestors 2Health News:Parents' Positive Attitude Can Help Kids Get Homework Done 2Health News:FDA Advisers Call for Revised Labels for Osteoporosis Drugs 2Health News:FDA Advisers Call for Revised Labels for Osteoporosis Drugs 3Health News:Microbes travel through the air; it would be good to know how and where 2Health News:Microbes travel through the air; it would be good to know how and where 3Health News:Study finds hospitals of last resort deliver lower quality of lung cancer care 2
    ... Nidek GYC-1000 delivers a solid-state ... of energy and plugs into ... compact design and extreme portability, ... with the Nidek Phaco Emulsification ...
    There are many reasons to choose the CardioGenesis 2000 Holmium:YAG Laser System for TMR in your hospital or medical facility. Among the first is the CardioGenesis commitment to deliver the highest q...
    Total T3 EIA Thyroid Function 025-BC-1005...
    ... The anti-TG test kit is a solid ... format. It is designed for the quantitative ... (TG) in serum or plasma. The microplate ... Calibrators, controls and patient samples are pipetted ...
    Medicine Products: